surmount studies tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT 1 // Three-Year Obesty

The differences come down to how each drug works, what it's best at, and which outcomes matter most to you

But while these treatments support metabolic health, they can also reduce appetite and affect nutrient absorption

Neurocutaneous Melanosis|NCM|Neurocutaneous Melanocytosis a large brown, blue, or gray hamartoma of dermal melanocytes, usually on the shoulder and upper arm that is most commonly found in asian populations and in females

For this reason, Wegovy should not be used in individuals with ca personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Mannino GC, Andreozzi F, Sesti G

doi: 10.1136/bmjdrc-2020-001420 59 IssarTKwaiNCGPoyntenAMArnoldRMilnerKLKrishnanAV